Sawgrass Asset Management LLC Lowers Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Sawgrass Asset Management LLC lowered its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 6.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,539 shares of the medical research company's stock after selling 3,595 shares during the period. Sawgrass Asset Management LLC's holdings in IQVIA were worth $9,931,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in IQV. FMR LLC lifted its holdings in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock worth $684,213,000 after acquiring an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in IQVIA in the 3rd quarter worth about $147,683,000. JPMorgan Chase & Co. lifted its stake in IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Nordea Investment Management AB boosted its position in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock valued at $277,908,000 after buying an additional 452,029 shares during the period. Finally, KBC Group NV grew its stake in shares of IQVIA by 68.5% during the fourth quarter. KBC Group NV now owns 616,299 shares of the medical research company's stock valued at $121,109,000 after buying an additional 250,458 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. William Blair restated an "outperform" rating on shares of IQVIA in a report on Wednesday, December 11th. The Goldman Sachs Group lowered their target price on shares of IQVIA from $280.00 to $250.00 and set a "buy" rating for the company in a research note on Friday, November 1st. Deutsche Bank Aktiengesellschaft reduced their price target on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. UBS Group reduced their price target on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a report on Friday, February 7th. Finally, BTIG Research downgraded shares of IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $251.67.

Insiders Place Their Bets

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the business's stock in a transaction that occurred on Tuesday, December 3rd. The shares were bought at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the acquisition, the director now owns 1,275 shares in the company, valued at $255,739.50. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.60% of the stock is currently owned by insiders.

IQVIA Stock Down 1.2 %

NYSE IQV traded down $2.40 during trading on Monday, hitting $193.65. The company's stock had a trading volume of 1,527,608 shares, compared to its average volume of 1,454,169. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The company has a market cap of $35.15 billion, a PE ratio of 25.82, a P/E/G ratio of 2.25 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.81. The business's 50 day simple moving average is $200.41 and its 200-day simple moving average is $217.82.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts anticipate that IQVIA Holdings Inc. will post 10.81 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.